Document is current
Any future updates will be listed below
-
Authors
Zimmermann, Tamara
Philipp, Edith
Marget-Muller, Sabine
Leclercq-Cohen, Gabrielle
Golling, Sabrina
Siebourg-Polster, Juliane
Augustin, Angelique
Villenave, Remi
- License Information
-
More Information
Article History
Received: 2 May 2025
Accepted: 24 November 2025
First Online: 6 December 2025
Declarations
:
: T. Zimmermann, E. Philipp, S. Marget-Müller, S. Golling, J. Siebourg-Polster, A. Augustin, and R. Villenave are employees of F. Hoffmann-La Roche Ltd and may hold Roche stock; G. Leclercq Cohen is an employee of Roche Pharma Research and Early Development, Roche Innovation Center Zurich. F. Hoffmann-La Roche markets tocilizumab (ACTEMRA ® /RoACTEMRA ® ), which was used as a reagent in this study. The authors declare no other competing interests.
